EVP, Chief Financial Officer Schneyer Mark C. sale 653 shares of ACADIA Pharmaceuticals Inc. [ACAD]

Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. ACADIA Pharmaceuticals Inc. shares valued at $11,695 were sold by Schneyer Mark C. on Jun 09. At $17.91 per share, Schneyer Mark C. sold 653 shares. The insider’s holdings dropped to 3,342 shares worth approximately $52202.04 following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Also, DAVIS STEPHEN sold 5,483 shares, netting a total of over 99,691 in proceeds. Following the sale of shares at $18.18 each, the insider now holds 75,875 shares.

Before that, Stankovic Srdjan R. had sold 2,865 shares from its account. In a trade valued at $52,091, the President traded ACADIA Pharmaceuticals Inc. shares for $18.18 each. Upon closing the transaction, the insider’s holdings decreased to 2,865 shares, worth approximately $0.86 million.

As published in a research note from Jefferies on June 21, 2022, ACADIA Pharmaceuticals Inc. [ACAD] has been rated down from a Buy to an Underperform and the price target has been revised to $10 from $25. This represents a -56.2% premium over Thursday’s closing price. Analysts at Jefferies upgraded the stock from ‘”a Hold”‘ to ‘”a Buy”‘ outlook in a report released in mid June. As of March 16, 2022, Canaccord Genuity has increased its “Hold” rating to a “Buy” for ACAD. Earlier on February 09, 2022, H.C. Wainwright upgraded its rating. Their new recommendation was “a Buy” for ACAD stock which previously was a “a Neutral”.

Analyzing ACAD’s Price Performance

On Thursday, ACADIA Pharmaceuticals Inc. [NASDAQ: ACAD] rose 4.34% to $15.62. The stock’s lowest price that day was $14.89, but it reached a high of $15.72 in the same session. During the last five days, there has been a surge of approximately 7.13%. Over the course of the year, ACADIA Pharmaceuticals Inc. shares have dropped approximately -33.08%. Shares of the company reached a 52-week high of $28.06 on 04/07/22 and a 52-week low of $12.24 on 06/21/22. A 50-day SMA is recorded $15.65, while a 200-day SMA reached $20.49. Nevertheless, trading volume fell to 1.8 million shares from 1.43 million shares the previous day.

Support And Resistance Levels for ACADIA Pharmaceuticals Inc. (ACAD)

According to the 24-hour chart, there is a support level at 15.10, which, if violated, would cause prices to drop to 14.58. In the upper region, resistance lies at 15.93. The next price resistance is at 16.24. RSI (Relative Strength Index) is 53.78 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.41, which suggests the price will decrease in the coming days. Percent R is at 9.45%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.

Is ACADIA Pharmaceuticals Inc. subject to short interest?

Stocks of ACADIA Pharmaceuticals Inc. saw a sharp steep in short interest on Jul 14, 2022 dropping by -2.0 million shares to 9.72 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 11.72 million shares. A decline of -20.58% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 2.15 of the overall float, the days-to-cover ratio (short ratio) decline to 2.15.

Which companies own the most shares of ACADIA Pharmaceuticals Inc. (ACAD)?

According to Baker Bros. Advisors LP filings, the company currently owns 41,976,594 shares, which is about 26.00% of the total ACAD shares outstanding. The investor’s shares have appreciated by 65,890 from its previous 13-F filing of 41910704.0 shares. With the completion of the sale transaction, Fidelity Management & Research Co’s stake is now worth $189,952,898. The Vanguard Group, Inc. acquire a 2.32% interest valued at $172.81 million while BlackRock Fund Advisors sold a -33,936 stake. A total of 2,930,886 shares of ACADIA Pharmaceuticals Inc. were sold by Ecor1 Capital LLC during the quarter, and 237,241 were bought by SSgA Funds Management, Inc. In its current portfolio, T. Rowe Price Associates, Inc. holds 4,978,936 shares valued at $70.15 million.

In terms of ACADIA Pharmaceuticals Inc. share price expectations, FactSet research, analysts set an average price target of $21.88 in the next 12 months, up nearly 33.6% from the previous closing price of $14.97. Analysts anticipate ACADIA Pharmaceuticals Inc. stock to reach $32.00 by 2022, with the lowest price target being $10.00. In spite of this, 20 analysts ranked ACADIA Pharmaceuticals Inc. stock as an Overweight at the end of 2022. On January 05, 2022, Citigroup assigned a price target of “a Buy” to the stock and upgraded coverage with a $30.


Please enter your comment!
Please enter your name here